In a derivative shareholder complaint on behalf of CytoDyn, a biotechnology company that specializes in HIV treatments, the former CEO demands rescission of excessive stock options awarded to the current CEO.
Categories / Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Additional Reads
-
-
Texans head to the polls for high-stakes US Senate primary February 17, 2026